Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03091803
Other study ID # 6B-16-1
Secondary ID NCI-2017-004996B
Status Withdrawn
Phase
First received
Last updated
Start date April 4, 2017
Est. completion date April 4, 2021

Study information

Verified date April 2021
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This randomized pilot clinical trial studies quantitative susceptibility mapping (QSM) and regional dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) permeability using golden-angle cartesian randomized time-resolved (GOCART) technique in evaluating regional gadolinium retention in the brain in patients with intracranial neoplasm receiving gadobenate dimeglumine or gadoterate meglumine. MRI diagnostic techniques such as, QSM and DCE MRI, may help to gather information regarding brain changes associated with gadolinium deposits during 8 to 18 months after administration of gadobenate dimeglumine or gadoterate meglumine.


Description:

PRIMARY OBJECTIVES: I. To obtain preliminary data (e.g. mean, variance, distribution) in the regional brain parenchymal changes associated with gadolinium (Gd) deposition during 8 to 18 months period after administration of gadolinium based contrast agents (GBCA) to Gd naive intracranial neoplasm patients who will be randomized to gadobenate dimeglumine (MultiHance) or gadoterate meglumine (Dotarem). II. To explore if areas of increased regional Gd deposition at individual level are correlated with baseline regional DCE permeability metrics such as volume transfer coefficient reflecting vascular permeability (kTrans), extracellular volume ratio reflecting vascular permeability (ve) and plasma volume (vp) in intracranial neoplasm patients. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo standard of care QSM and T1 weighted imaging (T1WI). Patients then receive gadobenate dimeglumine intravenously (IV) and undergo GOCART DCE MRI over 60 minutes. ARM II: Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes. After completion of study, patients are followed up at 8-18 months.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 4, 2021
Est. primary completion date April 4, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients) - Willingness to comply with the study protocol Exclusion Criteria: - Contraindications for MRI or GBCA (standard of care) - Abnormal renal function with estimated glomerular filtration rate (eGFR) less than 30 mL/min/m^2 based on creatinine obtained within last 30 days - History of previous administration of GBCA

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Undergo GOCART DCE MRI
Drug:
Gadobenate Dimeglumine
Given IV
Gadoterate Meglumine
Given IV
Device:
Magnetic Resonance Imaging
Undergo QSM and T1WI imaging

Locations

Country Name City State
United States USC / Norris Comprehensive Cancer Center Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in QSM score Descriptive statistics will be used to describe the magnitude of Gd deposition measured by QSM score in each of the two study groups. Histograms will be generated for QSM score at each time point as well as the change from the baseline for each group. The descriptive statistics will be used to calculate the mean, median, interquartile range, and standard deviation. Box plot and overlying histogram will be used to illustrate the distribution of change in Gd deposition between gadobenate dimeglumine and gadoterate meglumine group. Correlation between QSM score versus (vs.) kTrans and QSM score v Baseline up to 18 months
Secondary Change in T1WI signal intensity ratio Descriptive statistics will be used to describe the magnitude of Gd deposition measured by T1WI signal intensity ratio in each of the two study groups. Histograms will be generated for T1WI signal intensity ratio score at each time point as well as the change from the baseline for each group. The descriptive statistics will be used to calculate the mean, median, interquartile range, and standard deviation. Box plot and overlying histogram will be used to illustrate the distribution of change in Gd deposition between gadobenate dimeglumine and gadoterate meglumine group. Correlation between T1W Baseline up to 18 months
Secondary kTrans and Ve signal using GOCART 3D MRI The signal (kTrans and Ve) will be obtained in voxel level then taking average within the region of interest (ROI). ROI will be placed on the pons, bilateral globi pallidi, thalami and dentate nuclei to obtain the average signal within the ROI. Averages of all bilateral measurements will be used to calculate the final signal for kTrans and Ve. The final kTrans and Ve signal will only be used to assess the correlation with QSM and T1WI signal intensity ratios. Up to 18 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05732896 - Comparison of Opioid Consumption During TCI Guided by NOL Index or Standard Care Undergoing Intracranial Tumor Surgery N/A
Completed NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms Phase 2
Not yet recruiting NCT03717766 - Application of New Technologies in the Resection of Intracranial Tumors
Completed NCT05145049 - The Relationship of Anesthesia Method With Serum Lactate Level in Craniotomies
Terminated NCT03089749 - Characterization of Human Autoantibody Titers After Central Nervous System Insult
Not yet recruiting NCT05891002 - Accuracy of Robotically Assisted Cranial Biopsies
Recruiting NCT06291662 - Evaluation of Performance Characteristics and Applicability in Oncology of Devices Customized Medical Devices Made by 3D Printing N/A
Completed NCT04302857 - Tractography Pilot Study Leipzig
Completed NCT04454268 - Intracranial Hydatid Cyst N/A
Completed NCT03076255 - Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy N/A
Recruiting NCT04278118 - Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study N/A
Recruiting NCT03714347 - The Effect of Cerebral Oxygenation on Postoperative Recovery in Intracranial Surgery N/A
Completed NCT03710278 - The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)
Completed NCT03539731 - [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers Phase 1
Recruiting NCT05904704 - Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors N/A